BIO - Bio-Rad Laboratories, Inc.

NYSE - Nasdaq Real-time price. Currency in USD
256.06
+0.77 (+0.30%)
As of 12:30PM EST. Market open.
Stock chart is not supported by your current browser
Previous close255.29
Open255.45
Bid256.18 x 100
Ask256.51 x 100
Day's range255.26 - 256.59
52-week range169.19 - 268.40
Volume29,966
Avg. volume177,609
Market cap7.64B
Beta0.89
PE ratio (TTM)506.05
EPS (TTM)0.51
Earnings date30 Oct 2017 - 3 Nov 2017
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est272.50
Trade prices are not sourced from all markets
  • Bio-Rad (BIO) Beats Earnings and Revenue Estimates in Q3
    Zacks8 days ago

    Bio-Rad (BIO) Beats Earnings and Revenue Estimates in Q3

    Balanced growth across all geographical regions as well as many key life science and diagnostics product areas helps Bio-Rad (BIO) to drive the top and bottom line in Q3.

  • Associated Press15 days ago

    Bio-Rad posts 3Q profit

    On a per-share basis, the Hercules, California-based company said it had profit of 91 cents. The maker of instruments used in biomedical research posted revenue of $535 million in the period. For the current ...

  • Associated Press19 days ago

    Bio-Rad tops Street 3Q forecasts

    On a per-share basis, the Hercules, California-based company said it had profit of 91 cents. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • Business Wire19 days ago

    Bio-Rad Reports Third-Quarter 2017 Financial Results

    Bio-Rad Laboratories, Inc. , a global provider of life science research and clinical diagnostic products, announced financial results today for the third quarter ended September 30, 2017.

  • Business Wirelast month

    Bio-Rad to Report Third-Quarter 2017 Financial Results Thursday, November 2, 2017

    Bio-Rad Laboratories, Inc. , a global provider of life science research and clinical diagnostic products, will report financial results for the third quarter 2017 on Thursday, November 2, 2017, following the close of the market.

  • Business Wirelast year

    Microbiome MDx specialist Genetic Analysis and Bio-Rad Sign Agreement

    Genetic Analysis (GA) and Bio-Rad Laboratories, Inc., a global provider of life science research and clinical diagnostic products, today announced that they have signed an agreement in which Genetic Analysis will receive an equity investment from Bio-Rad in exchange for commercialization rights, in certain territories, for Genetic Analysis’s GA-map™ technology to detect gut dysbiosis. Terms of the agreement were not disclosed.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes